SCHEMBL1312946

SCHEMBL1312946

COC(=O)c1sc(-c2ccccn2)nc1C

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.76
KDM4E B2RXH2 4/20 0.73
GAA P10253 1/20 0.73
KMT2A Q03164 5/20 0.72
ALDH1A1 P00352 4/20 0.72
MAPT P10636 4/20 0.58
HPGD P15428 2/20 0.58
POLB P06746 1/20 0.58
RAB9A P51151 5/20 0.57
NPC1 O15118 3/20 0.52
APOBEC3G Q9HC16 1/20 0.50
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
TSHR P16473 2/20 0.48
TRPM8 Q7Z2W7 1/20 0.48
MAPK1 P28482 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28364602 0.86 LMNA (1.00) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL29783027 0.84 ALDH1A1 (1.00) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL596082 0.84 KDM4E (1.00) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL1574901 0.84 ALDH1A1 (1.00) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL7063637 0.83 KDM4E (0.76) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL3076150 0.83 KDM4E (0.76) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL1314395 0.82 LMNA (0.56) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL20646838 0.81 ALDH1A1 (0.72) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL20646835 0.81 KDM4E (0.72) LMNAKDM4EGAAKMT2AALDH1A1
SCHEMBL27889960 0.81 KMT2A (0.55) LMNAKDM4EGAAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2375899-B1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES ARRAY BIOPHARMA INC (US) 2015-02-25 EP disclosed
EP-2375899-B1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES ARRAY BIOPHARMA INC (US) 2015-02-25 EP disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed
EP-2375899-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF Array Biopharma, Inc. (US) 2011-10-19 EP disclosed
US-7790723-B2 Thiazole derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2010-09-07 US disclosed
WO-2010080864-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-07-15 WO disclosed
WO-2010080864-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-07-15 WO disclosed
US-20050222160-A1 Thiazole derivatives as phosphodiesterase iv inhibitors MERCK PATENT GMBH (DE) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF NOS1, NOS2, ASS1 LMNA 1149/4885KDM4E 1611/4885GAA 802/4885
US-20050222160-A1 Thiazole derivatives as phosphodiesterase iv inhibitors PDE3B, PDE4B, PDE4A LMNA 3271/4885KDM4E 1126/4885GAA 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.